Fisher & Paykel Healthcare

Fisher & Paykel Healthcare We are a leading designer, manufacturer and marketer of products for use in respiratory care, acute care, and the treatment of obstructive sleep apnea.

Fisher & Paykel commenced business in 1934 as an importer of refrigerators and washing machines. In 1938 F&P started manufacturing white-ware under license to several major international appliance companies and in the mid-1960s moved to manufacturing products using in-house technology. The involvement in healthcare started in the late 1960s when F&P sought involvement in a business that could bene

fit from their growing manufacturing and electronic expertise. A prototype respiratory humidifier, developed in New Zealand for use with patients needing ventilation in hospital intensive care situations, was taken to production by F&P. Since then we have consistently developed innovations to improve patient care and developed world-wide distribution for these products. On 14 November 2001, as part of a reorganisation, Fisher & Paykel Industries Limited was renamed Fisher & Paykel Healthcare Corporation Limited and a new company, Fisher & Paykel Appliances Holdings Limited, was established to own F&P’s appliances and finance business. In connection with the reorganisation, Fisher & Paykel Healthcare Corporation Limited listed on the Australian and New Zealand Stock Exchanges and NASDAQ. In February 2003 the NASDAQ listing was terminated.

29/07/2026

The F&P WigglewiNG™ is a tidy, ready-made solution that is used in conjunction with the F&P Optiflow™ Junior 2 Nasal Interface range to stabilize a nasogastric (NG) tube to the patient, while maintaining the ability to remove or reposition the interface if necessary.

Learn more about WigglewiNG: https://ap1.hubs.ly/H0162Tr0

Products may not be available in all countries. Please consult the Instructions for Use (IFU) for each device for more information.

28/07/2026

Why does the design matter?

Nasal high flow (NHF) therapy delivers heated, humidified air and oxygen at high flows to spontaneously breathing infants, making it a gentle and effective option.

A well-designed NHF interface ensures adequate flow delivery, reduces CO2 rebreathing, and supports mucosal health, helping to minimize complications such as nasal trauma.

Learn more about how Optiflow™ Junior 2 has been thoughtfully designed with the unique needs of neonates, infants and children in mind, at the link below:

https://ap1.hubs.ly/H015-710

*Products may not be available in all countries. Please consult the Instructions for Use (IFU) for each device for more information.

28/07/2026

What are the key ‘ingredients’ of a Nasal High Flow protocol?

Create a NHF ‘recipe’ for your department or hospital here:
https://ap1.hubs.ly/H016F4G0

28/07/2026

Results from the recently released clinical paper, the RENOVATE Randomized Clinical Trial (JAMA, 2024), suggest that high-flow nasal oxygen can serve as a safe-bridge therapy while the underlying cause of acute respiratory failure is determined, and the most appropriate respiratory support is ultimately implemented. Visit our webpage to explore this new clinical evidence, and download our infographic that captures the study methods and results.

https://ap1.hubs.ly/H0182rn0

21/07/2026

The RENOVATE Randomized Clinical Trial (JAMA, 2024) presents new evidence demonstrating the supportive role high-flow nasal oxygen may play across the hospital care continuum.

Visit our webpage for additional key research findings and to download an at-a-glance infographic that summarizes the study.

https://ap1.hubs.ly/H016F4F0

21/07/2026

🍰 Watch this Micro Moment to learn about the evidence based ‘ingredients’ that form a Nasal High Flow protocol or algorithm.

Learn more: https://ap1.hubs.ly/H016FgC0

14/07/2026

Why does the interface matter?

Preterm birth interrupts normal lung development, often resulting in stiff, underdeveloped lungs that lack surfactant. While many infants breathe spontaneously, others require noninvasive respiratory support to maintain functional residual capacity (FRC), reduce work of breathing, and improve gas exchange.

The interface used to deliver CPAP therapy can significantly influence clinical outcomes by ensuring the intended pressure is delivered.

Explore the design story behind the F&P FlexiTrunk™ CPAP interface, and how our fully integrated system is designed to improve care and outcomes for the tiniest patients, at the link below:

https://ap1.hubs.ly/H015NGl0

*Products may not be available in all countries. Please consult the Instructions for Use (IFU) for each device for more information.

12/07/2026

In those first moments of life, the right care makes all the difference. That’s why leading guidelines recommend T-piece resuscitators, such as the F&P Neopuff™, for controlled, consistent respiratory support at birth. Every breath counts. Discover how F&P Neopuff helps give babies the best start: http://qr.fph.co/bgv7Gk

Products may not be available in all countries. Please consult the Instructions for Use (IFU) for each device for more information.

Join us at NeoHeart 2026 in the Snow Room and discover how Fisher & Paykel Healthcare is helping to advance neonatal and...
03/07/2026

Join us at NeoHeart 2026 in the Snow Room and discover how Fisher & Paykel Healthcare is helping to advance neonatal and pediatric care.

To learn more about what we do visit: http://qr.fph.co/bgu3UB

30/06/2026

Why does the device matter?

At birth, a newborn’s transition from fluid-filled lungs to air-breathing life is critical and complex. The device used to deliver intermittent positive pressure ventilation (IPPV) can significantly influence clinical outcomes.

Studies show T-piece resuscitators (TPRs), such as the F&P Neopuff™ T-piece resuscitator, can provide more consistent and controlled pressures than self- or flow-inflating bags, reducing the risk of complications like barotrauma caused by excessive pressures.

Discover why device choice plays a critical role in neonatal resuscitation and explore the purpose behind the design of our IPPV therapy products for the most vulnerable patient population: http://qr.fph.co/bgtoFl

*Products may not be available in all countries. Please consult the Instructions for Use (IFU) for each device for more information.

Address

15 Maurice Paykel Place, East Tamaki
Auckland
2013

Alerts

Be the first to know and let us send you an email when Fisher & Paykel Healthcare posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share